These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 32404282)

  • 21. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
    Menendez JA; Mehmi I; Lupu R
    Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells.
    Nguyen Hoang AT; Hoe KL; Lee SJ
    PLoS One; 2021; 16(4):e0246264. PubMed ID: 33861751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
    Labriola L; Salatino M; Proietti CJ; Pecci A; Coso OA; Kornblihtt AR; Charreau EH; Elizalde PV
    Mol Cell Biol; 2003 Feb; 23(3):1095-111. PubMed ID: 12529413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
    Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
    Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parabens and Human Epidermal Growth Factor Receptor Ligand Cross-Talk in Breast Cancer Cells.
    Pan S; Yuan C; Tagmount A; Rudel RA; Ackerman JM; Yaswen P; Vulpe CD; Leitman DC
    Environ Health Perspect; 2016 May; 124(5):563-9. PubMed ID: 26502914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
    Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
    Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
    Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
    Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines.
    Kirkegaard T; Yde CW; Kveiborg M; Lykkesfeldt AE
    Int J Oncol; 2014 Jul; 45(1):393-400. PubMed ID: 24819550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.
    Martin EC; Rhodes LV; Elliott S; Krebs AE; Nephew KP; Flemington EK; Collins-Burow BM; Burow ME
    Mol Cancer; 2014 Oct; 13():229. PubMed ID: 25283550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resveratrol inhibits heregulin-beta1-mediated matrix metalloproteinase-9 expression and cell invasion in human breast cancer cells.
    Tang FY; Chiang EP; Sun YC
    J Nutr Biochem; 2008 May; 19(5):287-94. PubMed ID: 17651959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015].
    Vanacker H; Bally O; Kassem L; Tredan O; Heudel P; Bachelot T
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S47-52. PubMed ID: 26118876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Andrographolide Exhibits Anticancer Activity against Breast Cancer Cells (MCF-7 and MDA-MB-231 Cells) through Suppressing Cell Proliferation and Inducing Cell Apoptosis via Inactivation of ER-α Receptor and PI3K/AKT/mTOR Signaling.
    Tohkayomatee R; Reabroi S; Tungmunnithum D; Parichatikanond W; Pinthong D
    Molecules; 2022 May; 27(11):. PubMed ID: 35684480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
    Tan M; Grijalva R; Yu D
    Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
    Zhang X; Diaz MR; Yee D
    Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
    Li Z; Zhu Q; Chen H; Hu L; Negi H; Zheng Y; Ahmed Y; Wu Z; Li D
    Cancer Lett; 2016 Jul; 377(1):32-43. PubMed ID: 27063095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
    Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression.
    Bowers LW; Cavazos DA; Maximo IX; Brenner AJ; Hursting SD; deGraffenried LA
    Breast Cancer Res; 2013; 15(4):R59. PubMed ID: 23880059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.